XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 21, 2021
Nov. 06, 2020
May 08, 2020
Apr. 05, 2019
Jan. 31, 2022
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Proceeds from sale of common stock under an at-the-market sales agreement, net           $ 0 $ 21,357,000  
April 2019 ATM Agreement                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Maximum proceeds   $ 60,000,000 $ 75,000,000 $ 150,000,000        
Number of Common Shares Issued (in shares)               15,851,391
Proceeds Received (Net of Broker Commissions and Fees )               $ 52,621,000
Registration Statement, July 2021                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Maximum proceeds $ 300,000,000              
Registration Statement, July 2021 | Common Stock                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Maximum proceeds $ 150,000,000              
Securities Purchase Agreement | Hanmi Pharmaceutical Co. Ltd. (“Hanmi”)                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Shares sold in public offering (in shares)         12,500,000      
Shares sold in public offering (in dollars per share)         $ 1.60      
Proceeds from sale of common stock under an at-the-market sales agreement, net         $ 20,000,000